Treprostinil PatchPump - SteadyMed Therapeutics

Drug Profile

Treprostinil PatchPump - SteadyMed Therapeutics

Alternative Names: Trevyent

Latest Information Update: 04 Apr 2017

Price : $50

At a glance

  • Originator SteadyMed Therapeutics
  • Class Antihypertensives; Prostaglandins; Small molecules; Vasodilators
  • Mechanism of Action Epoprostenol receptor agonists; Platelet aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pulmonary hypertension
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Clinical Phase Unknown Pulmonary hypertension

Most Recent Events

  • 03 Apr 2017 Cardiome announces intention to submit MAA to EMA for Pulmonary hypertension in Europe during 2017
  • 31 Mar 2017 USPTO rules in favor of SteadyMed in inter partes review against United Therapeutics' patent no. 8 497 393
  • 09 Jan 2017 SteadyMed Therapeutics announces intention to submit NDA to USFDA in Q2 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top